Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430091 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01430091: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT01430091 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01430091, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.
Interventions
- DRUG Prasugrel (clinical formulation)
- DRUG Prasugrel (Orally Disintegrating Tablet [ODT])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-09 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
What the finished NCT01430091 record still lists
NCT01430091 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which Prasugrel (clinical formulation) is the first listed.
NCT01430091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01430091 about?
NCT01430091 is a clinical study titled "A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet". This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.
What is the current status of trial NCT01430091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-09. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01430091?
The interventions under investigation include: Prasugrel (clinical formulation) (DRUG), Prasugrel (Orally Disintegrating Tablet [ODT]) (DRUG).
Who is sponsoring clinical trial NCT01430091?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01430091's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia